We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Tripeptide Drug Effectively Controls Metabolic Syndrome in Rodent Model

By LabMedica International staff writers
Posted on 21 Dec 2014
Print article
Image: The new peptide offers a triple hormone effect in a single-cell molecule (Photo courtesy of Indiana University).
Image: The new peptide offers a triple hormone effect in a single-cell molecule (Photo courtesy of Indiana University).
Promising results in reducing obesity and normalizing glucose metabolism obtained with a synthetic dipeptide drug have been enhanced by the addition of a molecule of a third hormone, glucagon.

Investigators at Indiana University (Bloomington, USA) had reported previously that a "unimolecular dual incretin" derived from an intermixed peptide sequence from the hormones GLP-1 and GIP corrected two causal mechanisms of diabetes-linked obesity, adiposity-induced insulin resistance, and pancreatic insulin deficiency more effectively than did selective mono-agonists. This superior efficacy translated across rodent models of obesity and diabetes, including db/db mice and ZDF rats, to primates (cynomolgus monkeys and humans).

Incretins are a group of gastrointestinal hormones that cause an increase in the amount of insulin released from the beta cells of the islets of Langerhans after eating, even before blood glucose levels become elevated. They also slow the rate of absorption of nutrients into the blood stream by reducing gastric emptying and may directly reduce food intake. Incretins also inhibit glucagon release from the alpha cells of the Islets of Langerhans. The two main candidate molecules that fulfill criteria for an incretin are glucagon-like peptide-1 (GLP-1) and gastric inhibitory peptide (also known as: glucose-dependent insulinotropic polypeptide or GIP). Both GLP-1 and GIP are rapidly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4).

In a paper published in the December 8, 2014, online edition of the journal Nature Medicine, the investigators and their colleagues at the German Research Center for Environmental Health (Neuherberg, Germany) discussed results obtained with a new tripeptide drug that comprised the previous GLP-1/GIP combination with the addition of the hormone glucagon. Glucagon enhanced the effects of the other two hormones by increasing energy expenditure.

Results obtained by treating a rodent model of metabolic syndrome with the tripeptide drug showed that the new compound specifically and equally targeted three receptors of GLP-1, GIP, and glucagon, and reduced the animals' body weight by about 30%, almost twice as much as the GLP-1/GIP double hormone.

"This peptide represents the first rationally designed, fully potent, and balanced triple agonist ever achieved in the treatment of any disease," said contributing author Dr. Richard DiMarchi, professor of chemistry at Indiana University. "The benefits of the previously reported individual co-agonists have been integrated to a single molecule of triple action that provides unprecedented efficacy to lower body weight and control metabolism."

Human clinical trials of the tripeptide drug are being managed by Roche (Basel, Switzerland).

Related Links:

Indiana University
German Research Center for Environmental Health
Roche


New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Silver Member
Apolipoprotein A-I Assay
Apo A-I Assay
New
Silver Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.